November 2017 Surety Medicine Teleconference:
Wednesday, 15 November 2017 will bring the next Surety Medicine Teleconference,
at 1 pm (1300 hrs) Eastern Time. The topic for November is "Emergency Essential Civilian Employees and the Personnel Reliability Program (PRP).” The Division Chief of U.S. Army Public Health Center Surety Medicine will present from Joint Base San Antonio, Texas.
To receive access information for attending the presentation by dial-in phone
audio or on your computer via Defense Collaboration Services (DCS), send an
email request to: firstname.lastname@example.org
SCHEDULE OF SURETY MEDICINE TELECONFERENCES FOR FY 2018
15 NOV 2017
Emergency Essential Civilian Employees and the PRP
13 DEC 2017
Diagnosis/Evaluation/Treatment of Laboratory Acquired
Alpha Virus Infections
17 JAN 2018
Screening for Dementia and Cognitive Impairments:
PRP Suitability & Reliability
21 FEB 2018
Ergonomics and the Personnel Reliability Program
21 MAR 2018
Updates in the Diagnosis and Treatment of Nerve & Vesicant
18 APR 2018
Hearing Conservation and Audiometric Testing in Surety Programs
16 MAY 2018
HIV: CD4 Counts, Antiretroviral Drugs, and Impaired Immune
Functions in PRP
27 JUN 2018
Medical Review Officer Functions, and Relevant PRP Interfaces
18 JUL 2018
Screening Diabetics for Reliability and Suitability in the PRP
15 AUG 2018
Case Studies in Personnel Reliability Program Surety Management
26 SEP 2018
Animal Worker Occupational Health Issues in the PRP
ALERT: FDA Simplifies Rule for Anthrax PEP
FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS
The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax. The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.
Additional information is available from the FDA at:
ALERT: Autoinjector Shelf Life Extension Program: UPDATED JULY 5, 2017
NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM: Many expiration date extensions for autoinjector medications expire in 2017!
Check any auto-injector medication stores you have. Select the link
below for additional information from the FDA.
The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labeled expiration dates, some are now extended to 2022. Complete FDA information related to the auto-injector shelf life extension program can be found at: http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .
Information on this page also includes the latest updates (6/26/2017) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors.